Next-Generation Antibody Therapeutics Market Size 2022: Pfizer, Roche, Bristol-Myers Squibb, Amgen, AstraZeneca, Bayer, Takeda Pharmaceuticals

Next-Generation Antibody Therapeutics Market research report contains a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies interspersed with relevant data. Furthermore, the report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment. It also examines market performance and the position of the market during the forecast period.

Get a FREE Sample Copy of this Report with Graphs and Charts at: https://www.reportsnreports.com/contacts/requestsample.aspx?name=5703683

Global Next-Generation Antibody Therapeutics Market: Key Players

Bristol-Myers Squibb
Pfizer
Roche
Bristol-Myers Squibb
Amgen
AstraZeneca
Bayer
Takeda Pharmaceuticals
Biogen
Seattle Genetics
ImmunoGen
Kyowa Hakk-Kirin
Xencor
Dyax Corp

Product Overview
Use of a new improvised therapeutic antibody t-form novel medicines for the treatment of different diseases includes next-generation antibody therapeutics. Next-generation antibody therapeutics have been clinically developed for many diseases by pharmaceutical and biotechnology firms. Next-generation antibody-based therapeutics for the treatment of different medical conditions such as cancer, infectious diseases, and autoimmune diseases improve the current properties of therapeutic antibodies. For the reason of their unique pharmacological characteristics, the science and development involved in the production of next-generation antibodies generate great interest for many biotech and pharmaceutical companies, increase specificity for established cell types, and low intrinsic toxicity. Sacituzumab govitecan, an antibody-drug conjugate (ADC) composed of a humanized anti-Trop-2 antibody conjugated t-SN38 is studied for the treatment of patients with metastatic triple-negative breast cancer. Immunomedics, a pharmaceutical company focusing on the development of antibody-drug conjugates for the treatment of cancer is planning clinical studies of the ADC in other cancers.

Market Highlights
Global next-generation antibody therapeutics market t-surpass USD 14.26 million by 2030 from USD 4.69 million in 2019 at a CAGR of 13.69% throughout the forecast period, i.e. 2019-30.
The worldwide increase in the occurrence of different chronic diseases, the increase in the use of therapeutic antibodies, the production and invention of new medicines, and the increase in research and development activities for the preparation of new therapies are the key factors that are fueling the worldwide rise in the demand for next-generation antibody therapeutics.

Global Next-Generation Antibody Therapeutics Market: Segments
Oncology Segment t-grow with the highest CAGR of XX.X% during 2019-30
Global Next-Generation Antibody Therapeutics Market is segmented by therapeutic area int-oncology and autoimmune/inflammatory. The greater market share in 2019 was accounted for by the oncology segment and is expected t-see the highest growth during the forecast period due t-the rising incidence of cancer globally. The key factors for market growth are the growing prevalence of cancer worldwide, where next-generation antibodies serve as the predominant therapy and new product launches.

Antibody-Drug Conjugates segment t-grow with the highest CAGR of XX.X% during 2019-30
Global Next-Generation Antibody Therapeutics Market is segmented by technology int-Antibody-Drug Conjugates (ADCs), Bispecific Antibodies, Fc-engineered Antibodies, Antibody Fragments and Antibody-like Proteins, Biosimilar Antibody Products. The greater market share in 2019 was accounted for by ADCs and is estimated t-dominate during the forecast period. One of the major developments in the next-generation antibody therapeutics market is the progress in ADC technology. The ADC technology combines the cytotoxic potential of chemotherapy and advantageous characteristics of antibodies, which leads t-high specificity and efficiency of ADCs.

Global Next-Generation Antibody Therapeutics Market: Market Dynamics
Drivers
Increasing investments in healthcare infrastructural development
During the forecast period, the global next-generation demand for antibody therapeutics is likely t-expand at a significant rate. This is largely due t-the success of antibody therapeutics for chronic conditions such as cancer and autoimmune diseases of the next generation. Generally speaking, antibody therapeutics have experienced clear scientific developments t-improve their effectiveness. Also, due t-technological developments in antibody therapeutics and increasing the prevalence of chronic diseases, the market is experiencing substantial growth. Moreover, the growth of the next-generation antibody therapeutics market is driven by increasing healthcare expenditure and growing R&D activities.

Increasing volume of chronic patients
A significant factor in boosting the market for next-generation antibody therapeutics would als-be the rising prevalence of chronic disorders. Also, the introduction of technology t-support R&D activities is another key factor anticipated t-drive the growth of the industry over the next few years. In the antibody therapeutics market, many governments are growing funding and grants for research activities. This, combined with rising spending on healthcare by both developed and developing countries, would als-drive demand growth during the forecast period.

Restraints
High cost involved in research and development for developing next-generation antibodies
Different governments have implemented numerous stringent rules and regulations relating t-the use of antibodies, which are significantly hampering the global demand for next-generation antibody therapeutics. Also, the high investment required for R&D activities and the preference among medical and healthcare professionals as well as patients for older-generation drug therapies are some of the major issues facing the global market during the forecast period.

Global Next-Generation Antibody Therapeutics Market: Regions
Global next-generation antibody therapeutics market is segmented based on regional analysis int-five major regions. These include North America, Latin America, Europe, APAC, and MENA. Global next-generation antibody therapeutics market in North America held the largest market share of XX.X% in the year 2019 and due t-growing R&D activities, technical advancements in antibody therapies, growing healthcare expenditure, and increasing government initiatives in this area, growth over the forecast period is expected t-be sustained. Also, the growth of the market is driven by the growing prevalence of chronic diseases and by the growing approval of new medicines. It is anticipated that the growing occurrence of multiple diseases, growing advances in therapeutic antibodies, evolving antibody technologies, rising demand for better healthcare services, and rapid growth in biosimilar antibodies and engineered antibodies will bring new opportunities for the region's next-generation therapeutic antibody industry.

Global next-generation antibody therapeutics market is further segmented by region into:
North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United States and Canada
Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey and Rest of Europe
APAC Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia, and Rest of APAC
Row Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa and Rest of MENA
Global Next-Generation Antibody Therapeutics Market: Recent Development
In June 2019, Xencor has initiated the first dose in patients in phase I clinical trial for XmAb22841, a bispecific antibody that targets CTLA-4 and LAG-3 receptor inhibitors for the treatment of advanced solid tumors. If successful, it will change the treatment landscape of patients suffering from advanced solid tumors throughout the world
In December 2018, Seattle Genetics, Inc in collaboration with Takeda Pharmaceutical Company Limited has reported in the press release that the ECHELON-2 phase III clinical trial demonstrated clinically meaningful outcomes of brentuximab vedotin in combination with CHP (cyclophosphamide, doxorubicin, and prednisone) for the treatment of CD30-Expressing Peripheral T-cell lymphomas. If SUCCESSFUL, it will bring a potential new treatment option t-patients suffering from peripheral T-cell lymphomas across the globe.

Global Next-Generation Antibody Therapeutics Market report als-contains analysis on:
Global next-generation antibody therapeutics market Segments:

By Therapeutic Area:

Oncology
Autoimmune/Inflammatory

By Technology:

Antibody-Drug Conjugates (ADCs)
Bispecific Antibodies
Fc-engineered Antibodies
Antibody Fragments and Antibody-like Proteins
Biosimilar Antibody Products
Next-generation antibody therapeutics Market Dynamics
Next-generation antibody therapeutics Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies Involved in the Market
Value Chain of the Market

Market Drivers and Restraints

Direct Purchase of Next-Generation Antibody Therapeutics Market Research Report at: https://www.reportsnreports.com/purchase.aspx?name=5703683

Contact Us:

Corporate Headquarters
Tower B5, office 101,
Magarpatta SEZ,
Hadapsar, Pune-411013, India
+ 1 888 391 5441
sales@reportsandreports.com

About Us:

ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets.

This release was published on openPR.